Has James Bearden, MD received payments from drug or device companies?

Yes. Drug and device makers reported $28,189 in general payments to James Bearden, MD across 480 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Bearden, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Bearden, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Bearden, MD

Hematology & Oncology · Spartanburg, SCNPI 1447256730

Payments from drug & device makers

$28,189in general payments, 2019–2025

Across 480 payments — averaging $58.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sirtex Medical Inc$17K
AstraZeneca$1K
Johnson & Johnson$1K
Novartis$779
E.r. Squibb & Sons, L.L.C.$707
Gilead$528
plus $7K from 54 others

What the payments were for

Food & beverage$11,25298%
Education$2102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sirtex Medical Inc	21	$16,755
AstraZeneca(2 entities)	35	$1,230
Johnson & Johnson	35	$1,027
Novartis	37	$779
E.r. Squibb & Sons, L.L.C.	33	$707
Gilead	20	$528
Pfizer	27	$445
Merck	23	$442
Incyte Corporation	14	$441
Genentech USA, Inc.	18	$429
Eisai Inc.	14	$382
Bristol Myers Squibb	19	$382
Sanofi	8	$360
Lilly USA, LLC	19	$332
Daiichi Sankyo Inc.	11	$331
Amgen	15	$298
Beigene USA, Inc.	3	$251
Inari Medical, Inc.	2	$192
Jazz Pharmaceuticals Inc.	3	$182
AbbVie	7	$175
Array Biopharma Inc	12	$173
Astellas Pharma US Inc	4	$156
Seagen Inc.	6	$127
Servier Pharmaceuticals LLC	2	$124
Sobi, Inc	7	$121
Global Blood Therapeutics, Inc.	1	$113
G1 Therapeutics, Inc.	3	$108
Bayer	5	$105
GSK	6	$103
Exelixis Inc.	6	$96
Ipsen Biopharmaceuticals, Inc	4	$83
Pharmacyclics LLC, An Abbvie Company	4	$80
Regeneron Healthcare Solutions, Inc.	4	$79
Agios Pharmaceuticals, Inc.	1	$69
Takeda Pharmaceuticals U.S.A., Inc.	3	$68
Tersera Therapeutics LLC	4	$66
Advanced Accelerator Applications	1	$61
Stemline Therapeutics Inc.	2	$57
Kyowa Kirin, Inc.	4	$56
Karyopharm Therapeutics Inc.	3	$52
Mirati Therapeutics, Inc.	2	$51
Pharmaessentia USA Corporation	2	$44
Lexicon Pharmaceuticals, Inc.	3	$41
Adaptive Biotechnologies Corporation	2	$40
AVEO Pharmaceuticals, Inc.	2	$38
CTI Biopharma Corp.	2	$38
Taiho Oncology, Inc.	2	$34
Dendreon Pharmaceuticals LLC	1	$33
Rigel Pharmaceuticals, Inc.	2	$32
AMAG Pharmaceuticals, Inc.	2	$27
Clovis Oncology, Inc.	2	$25
Geron Corporation	1	$25
Epizyme, Inc.	1	$23
Azurity Pharmaceuticals, Inc.	1	$22
Beone Medicines USA, Inc.	1	$20
Syndax Pharmaceuticals, Inc.	1	$19
Novocure Inc.	1	$18
EMD Serono, Inc.	1	$17
Springworks Therapeutics, Inc.	1	$17
ADC Therapeutics America, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,189 in reported general payments places this provider in the 70th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$28,055

Medicare patients

159

Services billed

325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	64	$1,238
Potassium Chloride	56	$1,064
Tamoxifen Citrate	34	$838
Celecoxib	11	$519
Temazepam	15	$259
Ibandronate Sodium	12	$208
Zolpidem Tartrate	37	$177
Allopurinol	12	$122
Lorazepam	30	$95

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Spartanburg

Ki ChungSpartanburg$4.7M
Vikas DemblaSpartanburg$3.2M
Tondre BuckSpartanburg$2.1M
Steven CorsoSpartanburg$88K
Michael HumeniukSpartanburg$76K
Isaac AlwineSpartanburg$31K
Stephen DyarGreenville$4.5M
Suzanne FanningGreenville$3.9M
Robert StuartCharleston$2.9M
William EdenfieldGreenville$1.7M

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →